Martindale Pharma improves Aurum pre-filled syringe packaging

Published: 9-Nov-2011
Packaging Regulatory

To ensure ease of use and improve patient safety

Martindale Pharma, a UK manufacturer and supplier of pharmaceutical specials, has made a number of improvements to its Aurum range of 11 pre-filled syringes.

The Aurum syringes are used for on-the-spot administration of drugs where high visibility and simple drug identification is crucial.

The Brentwood, Essex-based firm has redesigned the range to enhance ease of use and help improve patient safety. Specific improvements include new colour-differentiated packaging; colour-differentiated translucent boxes that confirm contents; and colour-differentiated labels. In addition the firm has improved tamper-evident labels and the packaging is latex-free and Luer Lock fitting.

The firm says its new colour-differentiated packaging meets national and international colour differentiation standards on syringe labelling and also the Royal College of Anaesthetists recommendations on syringe labelling in critical care.

See more

You may also like

Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

Read more
The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway

Trending Articles

  1. IMed Group appoints Spencer Keegan as Talent Acquisition Manager IMed confirms expansion of business and implements new recruitment services for clients
  2. SGS granted approval for resumption of human ADME using carbon-14 The approval allows SGS to resume carbon-14 human ADME studies at its clinical pharmacology unit in Antwerp, reinstating a specialised capability in early-phase clinical research across Europe
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    FDA grants approval for commercial manufacturing at Rezon Bio's Warsaw-Duchnice facility Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the US Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar
  4. NJM introduces next-generation Bronco 4 pressure-sensitive labeler New system simplifies labeling for pharmaceuticals, nutraceuticals and cosmetics
  5. Moderna granted marketing authorisation for COVID-19 vaccine in Europe The product is now Moderna's third in its respiratory vaccine portfolio to be authorised in the European Union, following the approval of Spikevax and mRESVIA

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Regulatory

CStone's sugemalimab approved by MHRA for Stage III NSCLC

The MHRA's decision marks the biopharma's second indication approved for the product in the UK, with a global commercial rollout for sugemalimab now actively underway
Regulatory

American Chemistry Council's statement to Trump: make chemistry in America again

The Council has released a statement ahead of the President's State of the Union Address, asking for policies that unlock domestic production and address unfair foreign practices
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Regulatory

NICE approves Opzelura cream as first UK treatment for non-segmental vitiligo

Incyte Biosciences UK has secured NICE approval for Opzelura (ruxolitinib) cream, granting eligible NHS patients with non-segmental vitiligo access to the first and only approved therapy in England shown to support facial re-pigmentation
Regulatory

CDA-AMC rejects Leqembi reimbursement despite Health Canada approval

After expressing disappointment about a separate insomnia ruling, Eisai has criticised a draft decision by Canada's drug agency not to recommend public reimbursement of Leqembi for early Alzheimer's disease
Regulatory

Shield Therapeutics’ ACCRUFeR becomes first FDA-approved oral iron for children 10+

The FDA's approval for ACCRUFeR (ferric maltol) to treat iron deficiency in children aged 10 and older makes it the first and only prescription oral iron therapy specifically approved for this pediatric population
Regulatory

Hansa Biopharma’s imlifidase BLA accepted for FDA review

The US Food and Drug Administration has accepted the company's Biologics License Application for imlifidase, a novel IgG-cleaving enzyme designed to enable HLA-incompatible kidney transplantation
Subscribe now